Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

The Prognostic Factors Affecting Survival in Muscle Invasive Bladder Cancer Treated with Radiotherapy

방사선치료를 받은 근 침윤성 방광암의 예후 인자

  • Chung Woong-Ki (Departments of Therapeutic Radiology, Chonnam National University Hospital) ;
  • Oh Bong-Ryoul (Departments of Urology, Chonnam National University Medical School, Chonnam National University Hospital) ;
  • Ahn Sung Ja (Departments of Therapeutic Radiology, Chonnam National University Hospital) ;
  • Nah Byung Sik (Departments of Therapeutic Radiology, Chonnam National University Hospital) ;
  • Kwon Dong-Deuk (Departments of Urology, Chonnam National University Medical School, Chonnam National University Hospital) ;
  • Park Kwangsung (Departments of Urology, Chonnam National University Medical School, Chonnam National University Hospital) ;
  • Ryu Soo-Bang (Departments of Urology, Chonnam National University Medical School, Chonnam National University Hospital) ;
  • Park Yang-IL (Departments of Urology, Chonnam National University Medical School, Chonnam National University Hospital)
  • 정웅기 (전남대학교 의과대학 치료방사선과학교실) ;
  • 오봉렬 (전남대학교 의과대학 비뇨기과학교실) ;
  • 안성자 (전남대학교 의과대학 치료방사선과학교실) ;
  • 나병식 (전남대학교 의과대학 치료방사선과학교실) ;
  • 권동득 (전남대학교 의과대학 비뇨기과학교실) ;
  • 박광성 (전남대학교 의과대학 비뇨기과학교실) ;
  • 류수방 (전남대학교 의과대학 비뇨기과학교실) ;
  • 박양일 (전남대학교 의과대학 비뇨기과학교실)
  • Published : 2002.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : This study analyzed the prognostic factors affecting the survival rate and evaluated the role of radiation therapy in muscle-invading bladder cancer. Materials and Methods : Twenty eight patients with bladder cancer who completed planned definitive radiotherapy in the Departments of Therapeutic Radiology and Urology, Chonnam National University Hospital between Jan. 1986 to Dec. 1998 were retrospectively analyzed. The reviews were peformed based on the patients' medical records. There were 21 males and 7 females in this study. The median of age was 72 years old ranging from 49 to 84 years. All patients were confirmed as having transitional cell carcinoma with histological grade 1 in one patient, grade 2 in 15, grade 3 in 9, and uninformed in 3. Radiation therapy was peformed using a linear accelerator with 6 or 10 MV X-rays. Radiation was delivered daily with a 1.8 or 2.0 Gy fraction size by 4 ports (anterior-posterior, both lateral, alternatively) or 3 ports (Anterior and both lateral). The median radiation dose delivered to the isocenter of the target volume was 61.24 Gy ranging from 59 to 66.6 Gy. The survival rate was calculated by the Kaplan-Meier method. Multivariate analysis was peformed on the prognostic factors affecting the survival rate. Results : The survival rate was $76\%,\;46\%,\;33\%,\;33\%$ at 1, 2, 3, 5 years, respectively, with 19 months of median survival. The potential factors of age (less than 70 years vs above 70), sex, diabetes mellitus, hypertension, hydronephrosis, 1-stage (T3a vs T3b), TUR, chemotherapy, total duration of radiotherapy, radiation dose (less than 60 Gy vs above 60 Gy), and the treatment response were investigated with uniand multivariate analysis. Un univariate analysis, the T-stage (p=0.078) and radiation dose (p=0.051) were marginally significant, and the treatment response (p=0.011) was a statistically significant factor on the survival rate. Multivariate analysis showed there were no significant prognostic factors affecting the survival rate. Conclusion : The treatment response and radiation dose are suggested as th은 statistically significant factors affecting the survival rate of muscle invasive bladder cancer. A Further prospective randomized study is needed to confirm these prognostic factors.

목적 : 근 침윤성 방광암에서 생존율에 영향을 주는 예후 인자를 분석하고 방사선 치료의 역할을 알아보고자 하였다. 대상 및 방법 : 1986년 1월부터 1998년 12월까지 전남대학교병원에서 근 침윤성 방광암으로 진단 받고 계획된 치료를 완료한 28명의 환자를 대상으로 후향적 분석을 시행하였다. 전체 28명 중 남자가 21명 여자가 7명이었으며 환자의 연령은 49세에서 84세까지 분포하였고 중앙값은 72세였다. 조직학적으로 모두 이행상피암으로 확진되었으며 grade 1은 1명, grade 2는 15명, grade 3는 9명, 불명인 경우가 3명이었다. 방사선치료는 선형가속기의 6 MV 또는 10 MV X-ray를 이용하였으며 일회선량은 1.8 내지 2.0 Gy로 3문 내지 4문 조사를 시행하였다. 투여된 총방사선량은 59 내지 66.6 Gy였고 중앙값은 61.24 Gy였다. 생존율은 Kaplan-Meier법으로 산출하였고 두 군간의 비교는 Log-rank test를 이용하였다. 생존율에 영향을 미치는 요인들을 Cox 비례위험모델로 다변량 분석하였다. 결과 : 생존율은 1, 2, 3, 5년에 각각 76, 46, 33, $33\%$로 나타났다. 중앙 생존 기간은 19개월이었다. 생존율에 영향을 미치는 가능성 있는 예후 인자로서 연령(70세 미만 대 이상), 성별, 당뇨병, 고혈압, 수신증 동반 여부, T-병기 (T3a 대 T3b 이상), TUR, 항암화학요법 여부, 방사선치료기간, 방사선량(60 Gy 미만 대 60 Gy 이상), 방사선치료반응정도를 분석에 포함시켰으며, 이들 중 단변량분석에서 T-병기(p=0.078)와 방사선량(p=0.051)이 통계학적 의의에 접근하였으며 방사선치료반응 정도(p=0.011)가 통계학적으로 의의 있게 나타났다. 그러나 다변량분석에서는 통계학적 의의를 가지는 인자가 없었다. 결론 : 근 침윤성 방광암에서 생존율에 미치는 예후 인자로 방사선량, 방사선치료반응 정도가 단변량분석에서 의미있게 나타났으나 다변량 분석에서는 확인되지 못하였으며 향후 더욱 많은 증례를 대상으로 이에 대한 전향적 무작위 임상 시험이 필요할 것으로 생각된다.

Keywords

References

  1. Pollack A, Zagars G and Swanson D. Muscle-invasive bladder cancer treated with external bearn radiotherapy: Prognostic factors. Int J Radiat Oncol Biol Phys 1994;30:267-277
  2. Gospodarowicz MK, Hawkins MV, Rawling GA, et al. Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: Failure analysis. J Urol 1989;142:1448-1454 https://doi.org/10.1016/S0022-5347(17)39122-X
  3. Mameghan H, Fisher R, Mameghan J, et al. Analysis of failure following definitive radiotherapy for invasive transitional cell carcinorna of the bladder. Int J Radiat Oncol Biol Phys 1995;31:247-254 https://doi.org/10.1016/0360-3016(94)E0135-7
  4. Arias F, Dominguez MA, Martinez E, et al. Chernotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. Int J Radiat Oncol Biol Phys 2000;47:373-378 https://doi.org/10.1016/S0360-3016(00)00444-2
  5. American Joint Committee on Cancer. Manual for staging of cancer. 5th ed. Philadelphia, New York; Lippincott Co, 1997:41-46
  6. Kaplan EL and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481 https://doi.org/10.2307/2281868
  7. Cox DR. Regression models and life tables. J R Statis Soc B 1972;34:187-220
  8. Jenkins BJ, Blandy JP, Caulfield MJ, et al. Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive bladder cancer. Br J Urol 1988;62:343-346 https://doi.org/10.1111/j.1464-410X.1988.tb04362.x
  9. DeNeve W, Lybeert ML, Goor C, et al. Radiotherapy for T2 and T3 carcinoma of the bladder : The influence of overall treatment time. Radiat Oncol 1995;36:183-188 https://doi.org/10.1016/0167-8140(95)01586-6
  10. Koiso K, Shipley W, Keuppens F, et al. The status of bladder preserving therapeutic strategies in the management of patients with muscle invasive bladder cancer. Int J Urol 1995;2(Suppl 2):49-57
  11. Maciejewski B and Majewski S. Dose fractionation and tumor repopulation in radiotherapy for bladder cancer. Radiother Oncol 1991;21:163-170 https://doi.org/10.1016/0167-8140(91)90033-D
  12. Dubben HH. Local control.$TCD_50$, and dose timeprescription habits in radiotherapy of head and neck tumors. Radioth Oncol 1994;32:197-200 https://doi.org/10.1016/0167-8140(94)90018-3
  13. Van Putten WLJ, Van der Sangen MJC, Hoekstra CJM and Levendag PC. Dose fractionation and overall treatment time in radiation therapy : The effects on local control for cancer of the larynx. Radioth Oncol 1994;30:97-108 https://doi.org/10.1016/0167-8140(94)90038-8
  14. Withers HR, Peters LJ, Taylor JMG, et al. Local control of carcinoma of the tonsil by radiation therapy: An analysis of patterns of fractionation in nine institutions. Int J Radiat Oncol Biol Phys 1995;33:549-562 https://doi.org/10.1016/0360-3016(95)00228-Q
  15. Saunders MI, Dlsche S, Barret A, Parmar MK, Harvey A and Gibson D. Randomized multicenter trial of CHART versus conventional radiotherapy in head and neck and nonsmall cell cancer: A interim report. Br J Cancer 1996;73:1455-1462 https://doi.org/10.1038/bjc.1996.276
  16. Horiot JC, Bontemps P, Van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers : results of the EORTC 22851 randomized trial. Radiother Oncol 1997;44:111-121 https://doi.org/10.1016/S0167-8140(97)00079-0
  17. Moonen L, Voet HVD, De Nus R, Horenblas S, Hart AAM and Bartelink H. Muscle invasive bladder cancer treated with external beam radiation: Influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys 1998;42:525-530 https://doi.org/10.1016/S0360-3016(98)00263-6
  18. Morisson R. The results of treatment of cancer of the bladder-a clinical contribution. Clin Radiol 1975;26:67-75 https://doi.org/10.1016/S0009-9260(75)80017-1
  19. Naslund I, Nilsson B and Littbrand B. Hyperfractionated radiotherapy of bladder cancer: A 10 year follow up of a randomized clinical trial. Acta Oncol 1994;33:397-402 https://doi.org/10.3109/02841869409098435
  20. Jacobsen AB, Lunde S, Ous S, et al. T2/T3 bladder carcinomas treated with definitive radiotherapy with emphasis on flow cvtometric DNA ploidy values. Int J Rad Oncol Biol Phys 1989;17:923-929 https://doi.org/10.1016/0360-3016(89)90137-5
  21. Turner S, Swindell R, Bowl N, et al. Bladder movement during radiation therapy for bladder cancer: Implication for treatment planning. Int J Radiat Oncol Biol Phys 1994;30:199-200
  22. Marks LB and Shipley WU. Techniques for external beam irradiation of patients with invasive carcinoma of the urinary bladder. In : Levitt, S. H., ed. Technologic basis of radiotherapy : Practical clinical applications, 2nd ed. Philadelphia : Lee & Febiger; 1992:335-341
  23. Sur RK, clinkard J, Jones WG, et al. Changes in target volume during radiotherapy treatment of invasive bladder cancer. Clin Oncol 1993;5:30-33 https://doi.org/10.1016/S0936-6555(05)80693-4
  24. Cole D, Durrant K, Robert J, et al. A pilot study of accelerated fractionation in the radiotherapy of invasive carcinoma of the bladder. Br J Radiol 1992;65:792-798 https://doi.org/10.1259/0007-1285-65-777-792
  25. Shipley WU, Prout GR Jr , Einstein AB, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 1987;258:931-935 https://doi.org/10.1001/jama.258.7.931
  26. Scher HI, Herr HW, Sternberg C, et al. Neoadjuvant chemotherapy for invasive bladder cancer. Experience with the MVAC regimen. Br J Urol 1989;64:250-256 https://doi.org/10.1111/j.1464-410X.1989.tb06008.x
  27. Sauer R, Dunst J, Altendorf-Hofmann A, et al. Radiotherapy with and without cisplatin in bladder cancer. Int J Radiat Oncol Biol Phys 1990;19:687-691 https://doi.org/10.1016/0360-3016(90)90497-8
  28. Begg A. Cisplatin and radiation: Interaction probabilities and other therapeutic possibilities. Int J Radiat Oncol Biol Phys 1990;19:1183-1189 https://doi.org/10.1016/0360-3016(90)90226-A
  29. Flentje M, Eble M and Haner U. Additive effects of cisplatin and radiation in human tumor cells under oxic conditions. Radiother Oncol 1992;24:60-63 https://doi.org/10.1016/0167-8140(92)90355-X
  30. Mothersill C, Seymour CB, Cusak A, O'Brien A, Butler M. The effect of radiation and cytotoxic platinum compounds on the growth of normal and tumor bladder explant cultures. Acta Oncol 1990;29:179-184 https://doi.org/10.3109/02841869009126542
  31. Tester W, Porter A, Asbell S, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993;25:783-790 https://doi.org/10.1016/0360-3016(93)90306-G
  32. Dunst J, Sauer R, Schott KM, Kuhn R, Wittekind C and Altendorf-Hofman A. Organ-sparing treatment of advanced A. Organ- sparing treatment of advanced bladder cancer. A 10-year experience. Int J Radiat Oncol Biol Phys 1994;30:261-266
  33. Sauer R, Birkenhake S, Khun R, Wittekind C, Schortt KM and Martus P. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. Int J Radiat Oncol Biol Phys 1998;40:121-127 https://doi.org/10.1016/S0360-3016(97)00579-8
  34. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group Phase II trial 8802. J Clin Oncol 1996;14:119-126 https://doi.org/10.1200/JCO.1996.14.1.119
  35. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy. Initial results of Radiation Therapy Oncology Group. 89-03. J Clin Oncol 1998;16:3576-3583 https://doi.org/10.1200/JCO.1998.16.11.3576